Details for Patent: 10,751,305

Which drugs does patent 10,751,305 protect, and when does it expire?

Patent 10,751,305 protects PLIAGLIS and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 10,751,305

Title:	Solid-forming topical formulations for pain control
Abstract:	Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.
Inventor(s):	Zhang; Jie (Salt Lake City, UT), Hull; Wade (Kaysville, UT), Vo; Ngoc Truc-Chi (Longueuil, CA)
Assignee:	Crescita Therapeutics Inc. (Mississauga, CA)
Application Number:	15/655,595
Patent Claim Types: see list of patent claims	Formulation;

Drugs Protected by US Patent 10,751,305

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006		DISCN	Yes	No			Y

International Family Members for US Patent 10,751,305

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011205730
Brazil	112012017554
Canada	2822220
China	102834096